NKTX Stock — Nkarta Inc.: Cash, EV, Pipeline

Share price

$2.83

Market cap

$202.7M

Cash

$182.8M

Enterprise value

$19.9M

Balance sheet

Cash	$182.8M
Debt	$0.0M
Net cash	$182.8M
Enterprise value	$19.9M
Basic shares	74.5M shares
Fully diluted shares	96.7M shares
Fully diluted market cap	$273.8M
Cash per share	$2.45

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading NKTX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
May 13 - Jun 24	NKX019	Phase 2	Lupus Nephritis; Primary Membranous Nephropathy	—
Nov 12 - Dec 24	NKX019	Phase 2	Systemic Sclerosis; Idiopathic Inflammatory Myopathies; Antineutrophil Cytoplasmic Antibody-Associated Vasculitis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

NKX019

Phase 2 · Active Modality: allogeneic CAR NK cell therapy

Target CD19

Partnerships University of California, Irvine (investigator-sponsored Phase 1 trial in myasthenia gravis); Columbia University Irving Medical Center (investigator-sponsored Phase 1 trial in SLE)

Indications

lupus nephritis (Ntrust-1) (Stage not disclosed)
primary membranous nephropathy (Ntrust-1) (Stage not disclosed)
systemic sclerosis / scleroderma (Ntrust-2) (Stage not disclosed)
idiopathic inflammatory myopathy (Ntrust-2) (Stage not disclosed)
ANCA-associated vasculitis (Ntrust-2) (Stage not disclosed)
rheumatoid arthritis (Ntrust-2) (Stage not disclosed)
myasthenia gravis (investigator-sponsored) (Stage not disclosed)
systemic lupus erythematosus (investigator-sponsored) (Stage not disclosed)

Status note Lead program. Ntrust-1 and Ntrust-2 are open-label dose-escalation Phase 1/2 trials; protocol amendments in April 2026 enable outpatient administration. Prior Phase 1 oncology study in B-cell malignancies closed enrollment in 2023; oncology deprioritized.

NKX101

Phase 1 · Active Modality: allogeneic CAR NK cell therapy

Target NKG2D ligands

Indications

hematologic malignancies (Stage not disclosed)

Status note Oncology Phase 1 studies for NKX019 and NKX101 closed patient enrollment in 2023 and were deprioritized to direct primary resources to NKX019 in autoimmune diseases. FDA orphan drug designation for NKX101 in acute myeloid leukemia granted December 2021.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	NKX019
Lead indication	Lupus Nephritis
Lead phase	Phase 2
Active trials	4
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06557265	Phase 2	Recruiting	Sponsor	NKTX	—	Lupus Nephritis; Primary Membranous Nephropathy	—
NCT06733935	Phase 2	Recruiting	Sponsor	NKTX	—	Systemic Sclerosis; Idiopathic Inflammatory Myopathies; Antineutrophil Cytoplasmic Antibody-Associated Vasculitis	—
NCT04623944	Phase 1	Active, not recruiting	Sponsor	NKTX	—	Relapsed/Refractory AML; AML, Adult; MDS	—
NCT05020678	Phase 1	Active, not recruiting	Sponsor	NKTX	—	Lymphoma, Non-Hodgkin; B-cell Acute Lymphoblastic Leukemia; Large B-cell Lymphoma	—
NCT06518668	Phase 1	Enrolling by invitation	Collaborator	Hospital for Special Surgery, New York	—	Systemic Lupus Erythematosus	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Nkarta, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

NKTX — Nkarta Inc.